Home > Rheumatology > EULAR 2021 > New Developments in Rheumatoid Arthritis > JAK inhibitors and bDMARDs show comparable effectiveness

JAK inhibitors and bDMARDs show comparable effectiveness

Presented By
Mr Andrei Barbulescu, Karolinska Institutet, Sweden
EULAR 2021
JAK inhibitors show comparable effectiveness to biologic (b)DMARDs in rheumatoid arthritis (RA). That was the main conclusion of a comprehensive comparison between JAK inhibitors and bDMARD users in Swedish RA patients. The oral administration and relatively low costs of JAK inhibitors are beneficial for RA patients. The first JAK inhibitors approved by the EMA, tofacitinib and baricitinib, have not been thoroughly compared with other biologics prescribed for RA. Therefore, Mr Andrei Barbulescu (Karolinska Institutet, Sweden) performed a comprehensive comparative analysis of JAK inhibitors and biological DMARDs. For the analysis, he used Swedish national data on RA clinical measurements from different registries. Mr Barbulescu compared patient characteristics, retention rates, and clinical responses of patients treated with JAK inhibitors or bDMARDs. Patients on JAK inhibitors (n=905, mean age 60) started their treatment later in the disease than no...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on